Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsPreferred Shares RepurchasedReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Metlife (MET) Shares Outstanding (2016 - 2026)

Metlife's Shares Outstanding history spans 18 years, with the latest figure at $646.0 million for Q1 2026.

  • Quarterly Shares Outstanding fell 4.05% to $646.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $646.0 million through Mar 2026, down 4.05% year-over-year, with the annual reading at $655.3 million for FY2025, 4.92% down from the prior year.
  • Shares Outstanding came in at $1.2 billion for Q1 2026, up from $655.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $1.2 billion in Q1 2026 to a low of $655.3 million in Q4 2025.
  • The 5-year median for Shares Outstanding is $769.2 million (2023), against an average of $861.7 million.
  • Year-over-year, Shares Outstanding soared 51.36% in 2023 and then crashed 41.79% in 2024.
  • Metlife's Shares Outstanding stood at $779.1 million in 2022, then decreased by 6.2% to $730.8 million in 2023, then fell by 5.69% to $689.2 million in 2024, then dropped by 4.92% to $655.3 million in 2025, then decreased by 1.42% to $646.0 million in 2026.
  • Per Business Quant, the three most recent readings for MET's Shares Outstanding are $646.0 million (Q1 2026), $655.3 million (Q4 2025), and $660.7 million (Q3 2025).